Skip to content

Fractionation trial of adjuvant radiation following immediate autologous breast reconstruction

Randomized trial of effect of two fractionation schedules of Adjuvant Radiation following Immediate Autologous Breast Reconstruction (ARIA-BR) on Patient Reported Outcome Measures and Toxicity. - ARIA-BR

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/01/007745
Enrollment
160
Registered
2017-01-25
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- 1.Histologically confirmed preinvasive or invasive, Stage I â?? III breast cancer at initial presentation 2. Considered for whole breast reconstruction 3. Merits adjuvant RT

Interventions

Intervention1: Hypofractionated radiotherapy: Patients will receive 40Gy in 15 fractions over 3 weeks Control Intervention1: Conventional radiotherapy: Patients will receive 50Gy in 25 fractions over

Sponsors

Dr Prof Rajendra Badwe
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Known case of pre-invasive or invasive breast carcinoma (any histological subtype) 2. Stage I â?? III (Operable breast cancer or Locally Advanced breast cancer) at initial presentation 3. Age > 18 years 4. Undergone IBR following total mastectomy. 5. Eligible for adjuvant RT as per institutional protocol 6. Willing to give written informed consent.

Exclusion criteria

Exclusion criteria: 1. Histological diagnosis of phyllodes or sarcoma of the breast 2. Male breast cancer 3. History of receipt of previous RT to the chest wall 4. Pregnant unless willing to terminate pregnancy prior to initiation of radiotherapy

Design outcomes

Primary

MeasureTime frame
1.Satisfaction with breast reconstruction and outcome of surgery 2.Late normal tissue effects (shrinkage / fibrosis of reconstructed breast) Timepoint: 1.Satisfaction with breast reconstruction and outcome of surgery 2.Late normal tissue effects (shrinkage / fibrosis of reconstructed breast)

Secondary

MeasureTime frame
1. Health related Quality of life (HRQOL) 2. Complication rates like fat necrosis, infection, re-surgery 3. Influence of breast reconstruction on the radiation field design and technique 4. Clinical outcome: loco-regional control, disease free survival, distant metastasis free survival and overall survival at 2 and 5 years Timepoint: 2 and 5 years

Countries

India

Contacts

Public ContactTabassum Wadasadawala

TATA MEMORIAL HOSPITAL

drtabs.radonc@gmail.com27405078

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026